Evidence map›Paper›PMID 35078970›Full record

ArticleSignal transduction and targeted therapy2022

Whole-genome sequencing reveals the evolutionary trajectory of HBV-related hepatocellular carcinoma early recurrence.

Shao-Lai Zhou, Zheng-Jun Zhou, Cheng-Li Song, Hao-Yang Xin, Zhi-Qiang Hu, Chu-Bin Luo, Yi-Jie Luo, Jia Li, Zhi Dai, Xin-Rong Yang and 5 more

Open access · goldAbstract read
In one paragraph

Article in Signal transduction and targeted therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Shao-Lai Zhou *Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. zhoushaolai99@sina.com.ORCID http://orcid.org/0000-0002-8526-5221
Zheng-Jun Zhou *Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Cheng-Li Song *Novogene Bioinformatics Institute, Beijing, 100083, China.
Hao-Yang Xin *Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Zhi-Qiang HuDepartment of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Chu-Bin LuoDepartment of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Yi-Jie LuoNovogene Bioinformatics Institute, Beijing, 100083, China.
Jia LiDepartment of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Zhi DaiLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.ORCID http://orcid.org/0000-0002-4032-9201
Xin-Rong YangDepartment of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.ORCID http://orcid.org/0000-0002-2716-9338
Ying-Hong ShiDepartment of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Zheng WangDepartment of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Xiao-Wu HuangDepartment of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Jia FanDepartment of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.ORCID http://orcid.org/0000-0001-5158-629X
Jian ZhouDepartment of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. zhou.jian@zs-hospital.sh.cn.ORCID http://orcid.org/0000-0002-2118-1117
Sun Yat-sen University · CNFudan University · CNDalian Medical University · CNNovogene Bioinformatics Institute · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with hepatocellular carcinoma (HCC) have poor long-term survival following curative resection because of the high rate of tumor early recurrence. Little is known about the trajectory of genomic evolution from primary to early-recurrent HCC. In this study, we performed whole-genome sequencing (WGS) on 40 pairs of primary and early-recurrent hepatitis B virus (HBV)-related HCC tumors from patients who received curative resection, and from four patients whose primary and recurrent tumor were extensively sampled. We identified two recurrence patterns: de novo recurrence (18/40), which developed genetically independently of the primary tumor and carried different HCC drivers, and ancestral recurrence (22/40), which was clonally related to the primary tumor and progressed more rapidly than de novo recurrence. We found that the recurrence location was predictive of the recurrence pattern: distant recurrence tended to display the de novo pattern, whereas local recurrence tended to display the ancestral pattern. We then uncovered the evolutionary trajectories based on the subclonal architecture, driver-gene mutations, and mutational processes observed in the primary and recurrent tumors. Multi-region WGS demonstrated spatiotemporal heterogeneity and polyclonal, monophyletic dissemination in HCC ancestral recurrence. In addition, we identified recurrence-specific mutations and copy-number gains in BCL9, leading to WNT/β-catenin signaling activation and an immune-excluded tumor microenvironment, which suggests that BCL9 might serve as a new therapeutic target for recurrent HCC. Collectively, our results allow us to view with unprecedented clarity the genomic evolution during HBV-related HCC early recurrence, providing an important molecular foundation for enhanced understanding of HCC with implications for personalized therapy to improve patient survival.

Indexed as

Carcinoma, HepatocellularHepatitis B virusHumansLiver NeoplasmsNeoplasm ProteinsWhole Genome SequencingWnt Signaling PathwayNeoplasm Proteins

Identifiers

PMID35078970
PMCPMC8789859
OpenAlexW4210456230

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.